Immunology
Primary Sjogren's Syndrome
0
Pipeline Programs↗
2
Active Trials↗
8
Companies Involved↗
Primary Sjogren's Syndrome is an early-stage landscape with 0 programs across 8 companies. The most active players are Johnson & Johnson, Roche, Resolve Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Completed9 · 56%
Withdrawn3 · 19%
Unknown status2 · 13%
Not yet recruiting1 · 6%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
16 trials
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Active, not recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 1/2·NCT04496960·23 enrolled
A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome
Not yet recruiting·—·N/A·NCT07145060·105 enrolled
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Withdrawn·—·Phase 2/3·NCT04563195
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)